Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

5-day preoperative radiation for soft tissue sarcoma

Official title: Phase 2 5-Day Preoperative Radiation for Soft Tissue Sarcoma

Run by Stanford University · NCT06087861 · Data updated 2026-11-12

This study tests whether a shorter, five-day radiation treatment before surgery can safely help people with soft tissue sarcoma in their arms, legs, or abdomen just as well as the usual longer treatment.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment75 (estimated)
SponsorStanford University
Academic / other
Drugs / interventionschemotherapy, immunotherapy, radiation
Locations1 site (Palo Alto, California)
StatusRecruiting
StartedOctober 6, 2023
Main results expectedDecember 2027
Study endsDecember 2029
Registry record updatedJune 10, 2026
Trial IDNCT06087861 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with histologically confirmed soft tissue sarcoma who are scheduled for preoperative radiation and surgery.

Probably not a fit

Patients with a history of prior radiation to the treatment area or those currently undergoing other anti-cancer therapies may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and effectiveness of a shortened, five-day course of preoperative radiation therapy for patients diagnosed with soft tissue sarcoma located in the extremities, trunk, or retroperitoneum. This approach contrasts with the traditional 25-day radiation regimen, aiming to determine if a more condensed treatment can yield similar or improved outcomes. Participants will receive external beam radiotherapy as part of their preoperative care before surgical intervention.

Why it matters

Potential benefit: If successful, this study could lead to a more efficient and less burdensome preoperative treatment option for patients with soft tissue sarcoma.

How similar studies have gone: While the approach of abbreviated radiation therapy is being explored in various contexts, this specific five-day regimen for soft tissue sarcoma is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Histologically confirmed soft tissue sarcoma of the extremity, trunk or retroperitoneum.
2. Has been offered preoperative radiation and surgery as part of standard-of-care treatment
3. Age ≥ 18
4. KPS ≥ 70 or ECOG 0 to 2
5. Life expectancy ≥ 6 months
6. If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented.
7. Ability to understand and the willingness to personally sign the written IRB approved informed consent document.

Exclusion Criteria:

1. History of prior radiation to the area to be treated.
2. Active use of other anti-cancer investigational agents.
3. Planned use of concurrent chemotherapy, targeted therapy, or immunotherapy with radiation therapy (defined as the time interval starting 1 week before the first and last fraction of radiation therapy and surgery).
4. Pregnancy.

Where it's running

  • Stanford University
    Palo Alto, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • 68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients

    This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.

    Recruiting Phase 2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · Wuhan, Hubei · NCT07920835

  • Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma

    This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.

    Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07917949

  • Entinostat for pediatric soft tissue sarcoma with PAX abnormalities

    This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.

    Recruiting Phase 1 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07888114

  • Methionine-Reduced Diet in Solid Tumors (early-phase)

    A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

    Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

  • Preoperative Immunonutrition for bone and soft tissue sarcoma patients

    This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.

    Recruiting St. Anne's University Hospital Brno, Czech Republic · Brno · NCT07609329

  • Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

    This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

    Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.